# EarLy Treatment Response in nEoVascular Macular Degeneration With Eylea 8mg: ELEV8 A Prospective Observational Open Label Study Investigating the Fluid Dynamics During Early Response to Aflibercept 8mg in Patients With Exudative Age-related Macular Degeneration (AMD).

> **NCT07434713** · — · RECRUITING · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 50 (estimated)

## Conditions studied

- Age-Related Macular Degeneration (AMD)

## Interventions

- **DRUG:** treatment with Aflibercept 8mg (Eylea)

## Key facts

- **NCT ID:** NCT07434713
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-14
- **Primary completion:** 2026-03-27
- **Final completion:** 2026-03-27
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07434713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07434713, "EarLy Treatment Response in nEoVascular Macular Degeneration With Eylea 8mg: ELEV8 A Prospective Observational Open Label Study Investigating the Fluid Dynamics During Early Response to Aflibercept 8mg in Patients With Exudative Age-related Macular Degeneration (AMD).". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07434713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*